Drug intelligence / Profile preview

BPV9NO

Development stage: Preclinical
Modality: Small Molecules
Administration: Intrathecal

Overview

BPV9NO refers to a specific formulation of bupivacaine administered intrathecally at a dose of 9 mg, intended for patients with a body mass index (BMI) less than 27.5 kg/m². Bupivacaine is an amide-type local anesthetic that works by blocking sodium channels in nerve cells, thereby inhibiting the initiation and conduction of nerve impulses. This results in loss of sensation and pain relief, making it commonly used for regional anesthesia during surgical procedures such as knee arthroplasty[8].

Brand names: BPV9NOBPV-9NOBPV 9NO
Other names: intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on BPV9NO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPV9NO.

Explore the full profile